Peptide Drug Conjugates for targeted cancer treatment, with cellular targeting, stable drug carriers and efficient intracellular delivery of potent payloads.
Oncology drug development
Early drug development and preclinical optimization for solid and liquid tumors, with programs in initial oncology indications and partnering for further development.
Commercialisation of therapies
Development, launch and commercialisation of novel treatments, supported by many years of experience in the biopharmaceutical and oncology environment.
Knowledge
No knowledge articles yet
Once Phi Pharma SA has claimed this profile, we'll publish editorial articles and case studies here together.